Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

Journal of Lipid Research

Volumn 53, Issue 9, 2012, Pages 1755-1766

  Barter, Philip J ^a,b   Rye, Kerry Anne ^a,b,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atherosclerosis; CETP inhibition; Clinical trials; Drug therapy hypolipidemic drugs

Indexed keywords

ANACETRAPIB; ATORVASTATIN; BAY 605521; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DIABETES CONTROL; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; RISK; SMALL MOLECULE LIBRARIES;

EID: 84863789387     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R024075     Document Type: Review

References (88)

1. Di Angelantonio, E., N. Sarwar, P. Perry, S. Kaptoge, K. K. Ray, A. Thompson, A. M. Wood, S. Lewington, N. Sattar, C. J. Packard, et al. 2009. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 302:1993-2000.
2. Baigent, C., L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, et al. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376:1670-1681.
3. Barter, P., A. M. Gotto, J. C. LaRosa, J. Maroni, M. Szarek, S. M. Grundy, J. J. Kastelein, V. Bittner, and J. C. Fruchart. 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357:1301-1310. (Pubitemid 47481452)
4. Rye, K. A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 (Suppl.) : S195-S200.
5. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85:1234-1241. (Pubitemid 20123768)
6. Rubin, E. M., R. M. Krauss, E. A. Spangler, J. G. Verstuyft, and S. M. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:265-267. (Pubitemid 21896769)
7. Liu, A. C., R. M. Lawn, J. G. Verstuyft, and E. M. Rubin. 1994. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J. Lipid Res. 35:2263-2267.
8. Plump, A. S., C. J. Scott, and J. L. Breslow. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91:9607-9611. (Pubitemid 24297964)
9. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290:2292-2300. (Pubitemid 37430562)
10. Tardif, J. C., J. Gregoire, P. L. L'Allier, R. Ibrahim, J. Lesperance, T. M. Heinonen, S. Kouz, C. Berry, R. Basser, M. A. Lavoie, et al. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 297:1675-1682. (Pubitemid 46631626)
11. Barter, P. J., and M. E. Jones. 1980. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J. Lipid Res. 21:238-249. (Pubitemid 10115826)
12. Barter, P. J., G. J. Hopkins, and G. D. Calvert. 1982. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem. J. 208:1-7. (Pubitemid 13215389)
13. Barter, P. J., G. J. Hopkins, L. Gorjatschko, and M. E. Jones. 1982. A unified model of esterified cholesterol exchanges between human plasma lipoproteins. Atherosclerosis. 44:27-40. (Pubitemid 12093674)
14. Ha, Y. C., and P. J. Barter. 1982. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp. Biochem. Physiol. B. 71:265-269.
15. Hesler, C. B., T. L. Swenson, and A. R. Tall. 1987. Purification and characterization of a human plasma cholesteryl ester transfer protein. J. Biol. Chem. 262:2275-2282. (Pubitemid 17102658)
16. Drayna, D., A. S. Jarnagin, J. McLean, W. Henzel, W. Kohr, C. Fielding, and R. Lawn. 1987. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 327:632-634. (Pubitemid 17086900)
17. Qiu, X., A. Mistry, M. J. Ammirati, B. A. Chrunyk, R. W. Clark, Y. Cong, J. S. Culp, D. E. Danley, T. B. Freeman, K. F. Geoghegan, et al. 2007. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14:106-113.
18. Swenson, T. L., R. W. Brocia, and A. R. Tall. 1988. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J. Biol. Chem. 263:5150-5157.
19. Tall, A. R. 1993. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34:1255-1274. (Pubitemid 23230305)
20. Ihm, J., D. M. Quinn, S. J. Busch, B. Chataing, and J. A. Harmony. 1982. Kinetics of plasma protein-catalyzed exchange of phosphatidylcholine and cholesteryl ester between plasma lipoproteins. J. Lipid Res. 23:1328-1341. (Pubitemid 13165987)
21. Lagrost, L., and P. J. Barter. 1992. Cholesteryl ester transfer protein promotes the association of HDL apolipoproteins A-I and A-II with LDL: potentiation by oleic acid. Biochim. Biophys. Acta. 1127: 255-262.
22. Zhang, L., F. Yan, S. Zhang, D. Lei, M. A. Charles, G. Cavigiolio, M. Oda, R. M. Krauss, K. H. Weisgraber, K. A. Rye, et al. 2012. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat. Chem. Biol. 8:342-349.
23. Barter, P. J., Y. C. Ha, and G. D. Calvert. 1981. Studies of esterified cholesterol in sub-fractions of plasma high density lipoproteins. Atherosclerosis. 38:165-175. (Pubitemid 11138616)
24. Brown, M. L., A. Inazu, C. B. Hesler, L. B. Agellon, C. Mann, M. E. Whitlock, Y. L. Marcel, R. W. Milne, J. Koizumi, H. Mabuchi, et al. 1989. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:448-451. (Pubitemid 19277523)
25. Maruyama, T., N. Sakai, M. Ishigami, K. Hirano, T. Arai, S. Okada, E. Okuda, A. Ohya, N. Nakajima, K. Kadowaki, et al. 2003. Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis. 166:177-185. (Pubitemid 35449614)
26. Nagano, M., S. Yamashita, K. Hirano, M. Ito, T. Maruyama, M. Ishihara, Y. Sagehashi, T. Oka, T. Kujiraoka, H. Hattori, et al. 2002. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay. J. Lipid Res. 43:1011-1018. (Pubitemid 34760871)
27. Ritsch, A., H. Drexel, F. W. Amann, C. Pfeifhofer, and J. R. Patsch. 1997. Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler. Thromb. Vasc. Biol. 17:3433-3441. (Pubitemid 28028553)
28. Teh, E. M., P. J. Dolphin, W. C. Breckenridge, and M. H. Tan. 1998. Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America. J. Lipid Res. 39:442-456. (Pubitemid 28100681)
29. Whitlock, M. E., T. L. Swenson, R. Ramakrishnan, M. T. Leonard, Y. L. Marcel, R. W. Milne, and A. R. Tall. 1989. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J. Clin. Invest. 84:129-137. (Pubitemid 19170102)
30. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357:2109-2122. (Pubitemid 350146106)
31. Cannon, C. P., S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363:2406-2415.
32. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2159-2165.
33. Nicholls, S. J., H. B. Brewer, J. J. Kastelein, K. A. Krueger, M. D. Wang, M. Shao, B. Hu, E. McErlean, and S. E. Nissen. 2011. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 306:2099-2109.
34. Marcel, Y. L., C. Vezina, B. Teng, and A. Sniderman. 1980. Transfer of cholesterol esters between human high density lipoproteins and triglyceride-rich lipoproteins controlled by a plasma protein factor. Atherosclerosis. 35:127-133. (Pubitemid 10212368)
35. Krauss, R. M., K. Wojnooski, J. Orr, J. C. Geaney, C. A. Pinto, Y. Liu, J. A. Wagner, J. M. Luk, A. O. Johnson-Levonas, M. S. Anderson, et al. 2012. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J. Lipid Res. 53:540-547.
36. Johnson, W. J., M. C. Phillips, and G. H. Rothblat. 1997. Lipoproteins and cellular cholesterol homeostasis. Subcell. Biochem. 28: 235-276.
37. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater, H. Laks, et al. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88:2039-2046.
38. Cockerill, G. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15:1987-1994.
39. Nicholls, S. J., G. J. Dusting, B. Cutri, S. Bao, G. R. Drummond, K. A. Rye, and P. J. Barter. 2005. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 111:1543-1550. (Pubitemid 40470651)
40. Mineo, C., H. Deguchi, J. H. Griffin, and P. W. Shaul. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98: 1352-1364. (Pubitemid 43948059)
41. Bisoendial, R. J., G. K. Hovingh, J. H. Levels, P. G. Lerch, I. Andresen, M. R. Hayden, J. J. Kastelein, and E. S. Stroes. 2003. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 107:2944-2948. (Pubitemid 36736637)
42. Tso, C., G. Martinic, W. H. Fan, C. Rogers, K. A. Rye, and P. J. Barter. 2006. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 26: 1144-1149. (Pubitemid 43732125)
43. Seetharam, D., C. Mineo, A. K. Gormley, L. L. Gibson, W. Vongpatanasin, K. L. Chambliss, L. D. Hahner, M. L. Cummings, R. L. Kitchens, Y. L. Marcel, et al. 2006. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 98:63-72. (Pubitemid 43970204)
44. Sumi, M., M. Sata, S. Miura, K. A. Rye, N. Toya, Y. Kanaoka, K. Yanaga, T. Ohki, K. Saku, and R. Nagai. 2007. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27:813-818. (Pubitemid 46606711)
45. Abderrahmani, A., G. Niederhauser, D. Favre, S. Abdelli, M. Ferdaoussi, J. Y. Yang, R. Regazzi, C. Widmann, and G. Waeber. 2007. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia. 50: 1304-1314. (Pubitemid 46701553)
46. Fryirs, M. A., P. J. Barter, M. Appavoo, B. E. Tuch, F. Tabet, A. K. Heather, and K. A. Rye. 2010. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol. 30:1642-1648.
47. Drew, B. G., S. J. Duffy, M. F. Formosa, A. K. Natoli, D. C. Henstridge, S. A. Penfold, W. G. Thomas, N. Mukhamedova, B. de Courten, J. M. Forbes, et al. 2009. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 119:2103-2111.
48. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26:2552-2559. (Pubitemid 44607480)
49. Plump, A. S., L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A. R. Tall. 1999. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19:1105-1110. (Pubitemid 29177362)
50. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:73-75. (Pubitemid 23233459)
51. Föger, B., M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J. Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, et al. 1999. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274: 36912-36920.
52. MacLean, P. S., J. F. Bower, S. Vadlamudi, J. N. Osborne, J. F. Bradfield, H. W. Burden, W. H. Bensch, R. F. Kauffman, and H. A. Barakat. 2003. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler. Thromb. Vasc. Biol. 23:1412-1415. (Pubitemid 36994530)
53. Hayek, T., L. Masucci-Magoulas, X. Jiang, A. Walsh, E. Rubin, J. L. Breslow, and A. R. Tall. 1995. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J. Clin. Invest. 96:2071-2074.
54. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima. 1998. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:5033-5036. (Pubitemid 28108660)
55. Rittershaus, C. W., D. P. Miller, L. J. Thomas, M. D. Picard, C. M. Honan, C. D. Emmett, C. L. Pettey, H. Adari, R. A. Hammond, D. T. Beattie, et al. 2000. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:2106-2112.
56. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:203-207. (Pubitemid 30469005)
57. Morehouse, L. A., E. D. Sugarman, P. A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici. 2007. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48: 1263-1272. (Pubitemid 47312028)
58. Thompson, A., E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. Dullaart, B. Keavney, Z. Ye, and J. Danesh. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 299: 2777-2788. (Pubitemid 351846853)
59. Ridker, P. M., G. Paré, A. N. Parker, R. Y. Zee, J. P. Miletich, and D. I. Chasman. 2009. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18,245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2:26-33.
60. Voight, B. F., G. M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M. K. Jensen, G. Hindy, H. Hólm, E. L. Ding, T. Johnson, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. Epub ahead of print. May 17, 2012; doi:10.1016/S0140-6736(12)60312-2.
61. Curb, J. D., R. D. Abbott, B. L. Rodriguez, K. Masaki, R. Chen, D. S. Sharp, and A. R. Tall. 2004. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45: 948-953. (Pubitemid 38552866)
62. Moriyama, Y., T. Okamura, A. Inazu, M. Doi, H. Iso, Y. Mouri, Y. Ishikawa, H. Suzuki, M. Iida, J. Koizumi, et al. 1998. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev. Med. 27 : 659-667. (Pubitemid 28452494)
63. Clark, R. W., R. B. Ruggeri, D. Cunningham, and M. J. Bamberger. 2006. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47:537-552. (Pubitemid 43345595)
64. Nissen, S. E., J. C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, and E. M. Tuzcu. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356:1304-1316. (Pubitemid 46513296)
65. Kastelein, J. J., S. I. van Leuven, L. Burgess, G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, C. L. Shear, et al. 2007. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356: 1620-1630. (Pubitemid 46631671)
66. Bots, M. L., F. L. Visseren, G. W. Evans, W. A. Riley, J. H. Revkin, C. H. Tegeler, C. L. Shear, W. T. Duggan, R. M. Vicari, D. E. Grobbee, et al. 2007. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double- blind trial. Lancet. 370:153-160. (Pubitemid 47042895)
67. Barter, P. 2009. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am. J. Cardiol. 104:10E-15E.
68. Yvan-Charvet, L., F. Matsuura, N. Wang, M. J. Bamberger, T. Nguyen, F. Rinninger, X. C. Jiang, C. L. Shear, and A. R. Tall. 2007. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 27:1132-1138. (Pubitemid 46641969)
69. Nicholls, S. J., E. M. Tuzcu, D. M. Brennan, J. C. Tardif, and S. E. Nissen. 2008. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 118:2506-2514.
70. Forrest, M. J., D. Bloomfield, R. J. Briscoe, P. N. Brown, A. M. Cumiskey, J. Ehrhart, J. C. Hershey, W. J. Keller, X. Ma, H. E. McPherson, et al. 2008. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154: 1465-1473.
71. Hu, X., J. D. Dietz, C. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. Yuan, D. A. Perry, and J. Keiser. 2009. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 150:2211-2219.
72. Clerc, R. G., A. Stauffer, F. Weibel, E. Hainaut, A. Perez, J. C. Hoflack, A. Benardeau, P. Pflieger, J. M. Garriz, J. W. Funder, et al. 2010. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J. Hypertens. 28:1676-1686.
73. Sofat, R., A. D. Hingorani, L. Smeeth, S. E. Humphries, P. J. Talmud, J. Cooper, T. Shah, M. S. Sandhu, S. L. Ricketts, S. M. Boekholdt, et al. 2010. Separating the mechanism-based and offtarget actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation. 121:52-62.
74. Connelly, M. A., T. J. Parry, E. C. Giardino, Z. Huang, W. M. Cheung, C. Chen, F. Cools, H. Van der Linde, D. J. Gallacher, G. H. Kuo, et al. 2010. Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J. Cardiovasc. Pharmacol. 55:459-468.
75. Simic, B., M. Hermann, S. G. Shaw, L. Bigler, U. Stalder, C. Dorries, C. Besler, T. F. Luscher, and F. Ruschitzka. Torcetrapib impairs endothelial function in hypertension. Eur. Heart J. Epub ahead of print. September 14, 2011; doi: 10.1093/eurheartj/ehr348.
76. Barter, P. J., K. A. Rye, J. C. Tardif, D. D. Waters, S. M. Boekholdt, A. Breazna, and J. J. Kastelein. 2011. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 124:555-562.
77. Kuivenhoven, J. A., G. J. de Grooth, H. Kawamura, A. H. Klerkx, F. Wilhelm, M. D. Trip, and J. J. Kastelein. 2005. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95: 1085-1088. (Pubitemid 40544314)
78. Niesor, E. J., C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, H. Matile, G. Schmid, R. G. Clerc, E. Chaput, D. Blum-Kaelin, et al. 2010. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51:3443-3454.
79. Stroes, E. S., J. J. Kastelein, A. Benardeau, O. Kuhlmann, D. Blum, L. A. Campos, R. G. Clerc, and E. J. Niesor. 2009. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin- aldosterone system in rats. Br. J. Pharmacol. 158: 1763-1770.
80. Fayad, Z. A., V. Mani, M. Woodward, D. Kallend, M. Abt, T. Burgess, V. Fuster, C. M. Ballantyne, E. A. Stein, J. C. Tardif, et al. 2011. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 378:1547-1559.
81. Hermann, M., and F. T. Ruschitzka. 2009. The hypertension peril: lessons from CETP inhibitors. Curr. Hypertens. Rep. 11:76-80.
82. Lüscher, T. F., S. Taddei, J. C. Kaski, J. W. Jukema, D. Kallend, T. Munzel, J. J. Kastelein, and J. E. Deanfield. 2012. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J. 33: 857-865.
83. Schwartz, G. G., A. G. Olsson, C. M. Ballantyne, P. J. Barter, I. M. Holme, D. Kallend, L. A. Leiter, E. Leitersdorf, J. J. McMurray, P. K. Shah, et al. 2009. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158: 896-901.e3.
84. Castro-Perez, J., F. Briand, K. Gagen, S. P. Wang, Y. Chen, D. G. McLaren, V. Shah, R. J. Vreeken, T. Hankemeier, T. Sulpice, et al. 2011. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. 52: 1965-1973.
85. Ranalletta, M., K. K. Bierilo, Y. Chen, D. Milot, Q. Chen, E. Tung, C. Houde, N. H. Elowe, M. Garcia-Calvo, G. Porter, et al. 2010. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51:2739-2752.
86. Cao, G., T. P. Beyer, Y. Zhang, R. J. Schmidt, Y. Q. Chen, S. L. Cockerham, K. M. Zimmerman, S. K. Karathanasis, E. A. Cannady, T. Fields, et al. 2011. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res. 52:2169-2176.
87. Boettcher, M. F., R. Heinig, C. Schmeck, C. Kohlsdorfer, M. Ludwig, A. Schaefer, S. Gelfert-Peukert, G. Wensing, and O. Weber. 2012. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br. J. Clin. Pharmacol. 73:210-218.
88. Yvan-Charvet, L., J. Kling, T. Pagler, H. Li, B. Hubbard, T. Fisher, C. P. Sparrow, A. K. Taggart, and A. R. Tall. 2010. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30:1430-1438.